This 2021 rodent study investigated effects of Vitamin K₂ on salt-sensitive hypertension:

“Mice were supplemented with VK₂ and gut bacteria were detected by 16S rRNA. Common signaling pathway-related proteins were detected to further verify signaling pathways before validation of clinical samples.

Diets for 4 weeks were:

• Normal group diet containing 0.5% NaCl;
• High salt group (HS) diet containing 8% NaCl;
• High salt diet plus VK₂ supplementation group (HS_VK2) diet containing 8% NaCl and additional 0.025% VK₂.

VK₂ supplementation protected blood pressure and aortic vessels in salt-induced mice:

VK₂ treated salt-sensitive hypertension by inhibiting the renin–angiotensin system.

Possible mechanisms of VK₂ for salt-sensitive hypertension.”

https://www.frontiersin.org/articles/10.3389/fnut.2021.639467/full “Network and 16S rRNA Sequencing-Combined Approach Provides Insightal Evidence of Vitamin K₂ for Salt-Sensitive Hypertension”

The form of Vitamin K₂ was MK-4 per its C₃₁H₄₀O₂ molecular formula. Data wasn’t provided to calculate a human-equivalent dose for 0.025% MK-4.

This study was part of a 2022 Gut Microbial Response to Host Metabolic Phenotypes collection which included animal studies investigating gut microbiota in contexts of β-carotene and β-sitosterol supplementation. I found this collection by it citing the 2018 rodent study GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose which was Reference 27 of Dr. Paul Clayton’s blog post Sweet Nothing.